Nanyang Biologics (NYB) enters a strategic collaboration with NVIDIA, Hewlett Packard Enterprise (HPE), and Equinix to build “VECURA”—an artificial intelligence (AI)-powered drug discovery platform that combines advanced predictive models with a proprietary library of millions of natural compounds.
Through this initiative, NYB aims to accelerate the development of next-generation health solutions across pharmaceuticals, dietary supplements, functional foods, and personal care. Designed as an “AI-as-a-Service” platform, VECURA seeks to reduce the therapeutic drug discovery timeline from the traditional 10–12 years to just few hours.
The signing event marked the beginning of the collaboration with world renowned heavyweight company NVIDIA, HPE, and Equinix, to co-develop what will become a world-largest AI-curated compound library, anchored in Singapore.
Traditional drug discovery is often slow, costly, and inefficient, hindering the development of life-saving therapeutics. NYB’s VECURA seeks to transform this landscape by harnessing advanced technologies such as AI, machine learning, and virtual screening. Through curating a vast Natural Compound Library from tropical flora, and integrating cutting-edge metagenomics and metaproteomics analysis, VECURA can uncover the therapeutic potential hidden within diverse plants swiftly, enables rapid identification of promising drug candidates, significantly reducing discovery time and costs while opening new frontiers in personalized medicine and nature-based therapeutics.
